- Antheia received a conditional commitment from the Department of War's Office of Strategic Capital for a direct, long-term loan of up to $80 million, announced Oct 18, 2026.
- The financing, alongside private capital, would support Antheia's US manufacturing strategy to onshore critical pharmaceutical ingredients.
- The company cites US reliance on foreign countries for about 90 percent of key starting materials and active pharmaceutical ingredients.
- The commitment is conditional and requires Antheia to complete financial, legal, technical, investment and due diligence steps before financial close.
- Antheia previously received $32 million in non-dilutive federal financing and equity from strategic government-affiliated investors.
Quotes
“America's reliance on foreign suppliers for critical pharmaceutical ingredients has created ongoing public health and national security risks”
“Expanding our U.S. manufacturing footprint is central to our commercial strategy.”